drugset
drugset / Trial / NCT00483171

A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients

NCT00483171 ↗

Phase 3 Terminated 699 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if CP-945,598 is effective in the prevention of weight regain in obese subjects.

Timeline

Start
2008-01
Primary completion
2009-01
Completion
2009-01

Outcome

Outcome not reported

Stopped: “See termination reason in detailed description.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator OTENABANT Small molecule — —

Indications

obesity disorder